MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Myovant Sciences's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2022 was $-50.3 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2022 was $-143.7 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Myovant Sciences's annualized ROC % for the quarter that ended in Dec. 2022 was -131.76%. Myovant Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -2,076.75%.
EBIT is also linked to Joel Greenblatt's definition of earnings yield. Myovant Sciences's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2022 was -5.29%.
The historical data trend for Myovant Sciences's EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences Annual Data | ||||||||||||||||
Trend | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
EBIT | Get a 7-Day Free Trial | -141.00 | -264.25 | -275.57 | -244.40 | -186.96 |
Myovant Sciences Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
EBIT | Get a 7-Day Free Trial | -59.67 | -51.80 | -8.88 | -32.69 | -50.30 |
For the Biotechnology subindustry, Myovant Sciences's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
EBIT for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences (NYSE:MYOV) EBIT Explanation
1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Myovant Sciences's annualized ROC % for the quarter that ended in Dec. 2022 is calculated as:
ROC % (Q: Dec. 2022 ) | ||||||
= | NOPAT | / | Average Invested Capital | |||
= | Operating Income * ( 1 - Tax Rate % ) | / | ( (Invested Capital (Q: Sep. 2022 ) | + | Invested Capital (Q: Dec. 2022 )) | / count ) |
= | -207.58 * ( 1 - -2.14% ) | / | ( (161.457 | + | 160.385) | / 2 ) |
= | -212.022212 | / | 160.921 | |||
= | -131.76 % |
where
Invested Capital | (Q: Sep. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 483.974 | - | 113.298 | - | ( 371.29 | - | max(0, 251.691 | - | 460.91 | + | 371.29 | )) |
= | 161.457 |
Invested Capital | (Q: Dec. 2022 ) | |||||||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | Excess Cash | |||||||
= | Total Assets | - | Accounts Payable & Accrued Expense | - | ( Cash, Cash Equivalents, Marketable Securities | - | max(0, Total Current Liabilities | - | Total Current Assets | + | Cash, Cash Equivalents, Marketable Securities | )) |
= | 403.521 | - | 102.303 | - | ( 274.437 | - | max(0, 245.753 | - | 386.586 | + | 274.437 | )) |
= | 160.385 |
Note: The Operating Income data used here is four times the quarterly (Dec. 2022) data.
2. Joel Greenblatt's definition of Return on Capital:
Myovant Sciences's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2022 is calculated as:
ROC (Joel Greenblatt) % | (Q: Dec. 2022 ) | ||||||
= | EBIT | / | Average of (Net fixed Assets | + | Net Working Capital) | ||
= | EBIT | / | Average of (Property, Plant and Equipment | + | Net Working Capital) | ||
Q: Sep. 2022 | Q: Dec. 2022 | ||||||
= | EBIT | / | ( ( (Property, Plant and Equipment + Net Working Capital) | + | (Property, Plant and Equipment + Net Working Capital) ) | / | count ) |
= | -201.216 | / | ( ( (9.734 + max(-160.64, 0)) | + | (9.644 + max(-133.898, 0)) ) | / | 2 ) |
= | -201.216 | / | ( ( 9.734 | + | 9.644 ) | / | 2 ) |
= | -201.216 | / | 9.689 | ||||
= | -2,076.75 % |
where Working Capital is:
Working Capital | (Q: Sep. 2022 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (33.762 | + | 23.047 | + | 31.868) | - | (113.298 | + | 117.848 | + | 18.171) |
= | -160.64 |
Working Capital | (Q: Dec. 2022 ) | ||||||||||
= | (Accounts Receivable | + | Total Inventories | + | Other Current Assets) | - | (Accounts Payable & Accrued Expense | + | Defer. Rev. | + | Other Current Liabilities) |
= | (41.021 | + | 30.084 | + | 38.047) | - | (102.303 | + | 117.231 | + | 23.516) |
= | -133.898 |
When net working capital is negative, 0 is used.
Note: The EBIT data used here is four times the quarterly (Dec. 2022) EBIT data.
3. It is also linked to Joel Greenblatt's definition of Earnings Yield:
Myovant Sciences's Earnings Yield (Joel Greenblatt) % for today is calculated as:
Earnings Yield (Joel Greenblatt) % | = | EBIT (TTM) | / | Enterprise Value (Q: Dec. 2022 ) |
= | -143.674 | / | 2716.507 | |
= | -5.29 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Myovant Sciences's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020 |
Lauren Merendino | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David C Marek | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Matthew Lang | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Ferreira Juan Camilo Arjona | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Uneek Mehra | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Shigeyuki Nishinaka | director | 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Nancy Valente | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | officer: Principal Fin'l & Accounting | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Kim Sablich | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Hiroshi Nomura | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045 |
Adele M. Gulfo | director | ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957 |
From GuruFocus
By Value_Insider Value_Insider • 12-11-2022
By Value_Insider Value_Insider • 11-20-2022
By Business Wire Business Wire • 10-26-2022
By Business Wire Business Wire • 10-24-2022
By PRNewswire PRNewswire • 10-25-2022
By Marketwired • 09-26-2023
By PurpleRose PurpleRose • 08-06-2022
By PurpleRose PurpleRose • 07-18-2022
By PRNewswire PRNewswire • 07-15-2022
By Value_Insider Value_Insider • 10-14-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.